Literature DB >> 28329304

Cystic Fibrosis Pulmonary Exacerbations Attributable to Respiratory Syncytial Virus and Influenza: A Population-Based Study.

Ranjani Somayaji1,2, Christopher H Goss2, Umer Khan3, Moni Neradilek4, Kathleen M Neuzil5, Justin R Ortiz6.   

Abstract

BACKGROUND.: Characterization of the role of respiratory viral pathogens on cystic fibrosis (CF) pulmonary disease is needed. We aimed to determine the association of influenza and respiratory syncytial virus (RSV) activity with risk of pulmonary exacerbation (PEx) in persons with CF in the United States. METHODS.: We conducted a cohort study from January 2003 to March 2009 using the CF Foundation Patient Registry merged with Centers for Disease Control and Prevention respiratory virus surveillance data. The primary goal was to determine the association between regional influenza or RSV detections with risk of PEx requiring intravenous antibiotics or hospitalization. We analyzed outcomes by geographic region and week of event using multivariable regression models adjusted for demographic and clinical predictors of PEx stratified for children (<18 years) and adults (≥18 years) to calculate relative risks (RRs) of PEx. RESULTS.: There were 21022 individuals (52% male) in the CF patient cohort in 2003 comprised of 12702 children and 8320 adults. The overall incidence rate of PEx was 521.9 per 10000 person-months. In children, a 10% increase in the proportion of surveillance tests positive for influenza or RSV was significantly associated with increased PEx risk (RR, 1.02; 95% confidence interval [CI], 1.01-1.03) and (RR, 1.05; 95% CI, 1.02-1.07), respectively. In adults, surveillance tests positive for influenza (RR, 1.02; 95% CI, 1.01-1.02), but not RSV (RR, 0.99; 95% CI, .98-1.01), had a significant association with PEx risk. CONCLUSIONS.: Our large CF population-based cohort demonstrated a significant association between PEx risk and influenza activity in children and adults and with RSV activity in children.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  cystic fibrosis; influenza virus; pulmonary exacerbations; respiratory syncytial virus; surveillance

Mesh:

Year:  2017        PMID: 28329304      PMCID: PMC5848232          DOI: 10.1093/cid/cix203

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  37 in total

1.  Spirometric reference values from a sample of the general U.S. population.

Authors:  J L Hankinson; J R Odencrantz; K B Fedan
Journal:  Am J Respir Crit Care Med       Date:  1999-01       Impact factor: 21.405

Review 2.  Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies.

Authors:  Edward A Belongia; Melissa D Simpson; Jennifer P King; Maria E Sundaram; Nicholas S Kelley; Michael T Osterholm; Huong Q McLean
Journal:  Lancet Infect Dis       Date:  2016-04-06       Impact factor: 25.071

Review 3.  Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis.

Authors:  Christopher H Goss; Jane L Burns
Journal:  Thorax       Date:  2007-04       Impact factor: 9.139

4.  Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis.

Authors:  P A Piedra; S Grace; A Jewell; S Spinelli; D Bunting; D A Hogerman; F Malinoski; P W Hiatt
Journal:  Pediatr Infect Dis J       Date:  1996-01       Impact factor: 2.129

5.  Is there a role for influenza vaccination in cystic fibrosis?

Authors:  Dennis Wat; Colin Gelder; Sam Hibbitts; Ian Bowler; Marcus Pierrepoint; Rachel Evans; Iolo Doull
Journal:  J Cyst Fibros       Date:  2007-07-05       Impact factor: 5.482

6.  RSV mediates Pseudomonas aeruginosa binding to cystic fibrosis and normal epithelial cells.

Authors:  Bart E Van Ewijk; Tom F W Wolfs; Piet C Aerts; Kok P M Van Kessel; Andre Fleer; Jan L L Kimpen; Cornelis K Van der Ent
Journal:  Pediatr Res       Date:  2007-04       Impact factor: 3.756

7.  Monitoring influenza activity in the United States: a comparison of traditional surveillance systems with Google Flu Trends.

Authors:  Justin R Ortiz; Hong Zhou; David K Shay; Kathleen M Neuzil; Ashley L Fowlkes; Christopher H Goss
Journal:  PLoS One       Date:  2011-04-27       Impact factor: 3.240

8.  Respiratory viruses in children with cystic fibrosis: viral detection and clinical findings.

Authors:  Jane L Burns; Julia Emerson; Jane Kuypers; Angela P Campbell; Ronald L Gibson; Sharon McNamara; Kelly Worrell; Janet A Englund
Journal:  Influenza Other Respir Viruses       Date:  2011-09-29       Impact factor: 4.380

9.  Clinical manifestations of exacerbations of cystic fibrosis associated with nonbacterial infections.

Authors:  C G Pribble; P G Black; J A Bosso; R B Turner
Journal:  J Pediatr       Date:  1990-08       Impact factor: 4.406

Review 10.  Clinical review: primary influenza viral pneumonia.

Authors:  Jordi Rello; Aurora Pop-Vicas
Journal:  Crit Care       Date:  2009-12-21       Impact factor: 9.097

View more
  16 in total

1.  Rates of adverse and serious adverse events in children with cystic fibrosis.

Authors:  Jessica E Pittman; Umer Khan; Theresa A Laguna; Sonya Heltshe; Christopher H Goss; Don B Sanders
Journal:  J Cyst Fibros       Date:  2021-03-18       Impact factor: 5.482

Review 2.  Defining the Incidence and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Children with Chronic Diseases.

Authors:  Paolo Manzoni; Josep Figueras-Aloy; Eric A F Simões; Paul A Checchia; Brigitte Fauroux; Louis Bont; Bosco Paes; Xavier Carbonell-Estrany
Journal:  Infect Dis Ther       Date:  2017-06-26

3.  Seasonality of acquisition of respiratory bacterial pathogens in young children with cystic fibrosis.

Authors:  Kevin J Psoter; Anneclaire J De Roos; Jon Wakefield; Jonathan D Mayer; Margaret Rosenfeld
Journal:  BMC Infect Dis       Date:  2017-06-09       Impact factor: 3.090

4.  Viral respiratory tract infections in young children with cystic fibrosis: a prospective full-year seasonal study.

Authors:  Mathilde Eymery; Florence Morfin; Anne Doleans-Jordheim; Marie Perceval; Camille Ohlmann; Catherine Mainguy; Philippe Reix
Journal:  Virol J       Date:  2019-09-03       Impact factor: 4.099

5.  First Wave of COVID-19 in French Patients with Cystic Fibrosis.

Authors:  Harriet Corvol; Sandra de Miranda; Lydie Lemonnier; Astrid Kemgang; Martine Reynaud Gaubert; Raphael Chiron; Marie-Laure Dalphin; Isabelle Durieu; Jean-Christophe Dubus; Véronique Houdouin; Anne Prevotat; Sophie Ramel; Marine Revillion; Laurence Weiss; Loic Guillot; Pierre-Yves Boelle; Pierre-Régis Burgel
Journal:  J Clin Med       Date:  2020-11-10       Impact factor: 4.241

6.  SARS-CoV-2 (COVID-19) and cystic fibrosis.

Authors:  Bruce A Stanton; Thomas H Hampton; Alix Ashare
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-07-15       Impact factor: 5.464

Review 7.  Recent advances in the understanding and management of cystic fibrosis pulmonary exacerbations.

Authors:  Kate Skolnik; Bradley S Quon
Journal:  F1000Res       Date:  2018-05-14

8.  Impact of influenza on hospitalization rates in children with a range of chronic lung diseases.

Authors:  Nusrat Homaira; Nancy Briggs; Ju-Lee Oei; Lisa Hilder; Barbara Bajuk; Tom Snelling; Georgina M Chambers; Adam Jaffe
Journal:  Influenza Other Respir Viruses       Date:  2019-01-30       Impact factor: 4.380

9.  Influenza A Virus Pre-Infection Exacerbates Pseudomonas aeruginosa-Mediated Lung Damage Through Increased MMP-9 Expression, Decreased Elafin Production and Tissue Resilience.

Authors:  Berengère Villeret; Brigitte Solhonne; Marjolène Straube; Flora Lemaire; Aurélie Cazes; Ignacio Garcia-Verdugo; Jean-Michel Sallenave
Journal:  Front Immunol       Date:  2020-02-13       Impact factor: 7.561

10.  Clinical impact of respiratory virus in pulmonary exacerbations of children with Cystic Fibrosis.

Authors:  Viviane Mauro Correa Meyer; Marilda Mendonça Siqueira; Patricia Fernandes Barreto Machado Costa; Braulia Costa Caetano; Jonathan Christian Oliveira Lopes; Tânia Wrobel Folescu; Fernando do Couto Motta
Journal:  PLoS One       Date:  2020-10-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.